Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Genus plc    GNS   GB0002074580

GENUS PLC

(GNS)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Genus : shares surge on deal to market gene-edited pigs in China

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/16/2019 | 07:51am EDT

BEIJING (Reuters) - British livestock genetics firm Genus agreed on Thursday to licence its know-how on virus-resistant pigs to Beijing Capital Agribusiness Co Ltd, which will seek regulatory approval for the pigs in the world's biggest pork market.

Genus has a global patent for commercialisation of pigs genetically edited to resist Porcine Reproductive and Respiratory Syndrome (PRRS), also known as blue-ear disease, which causes billion-dollar losses for the global pig industry each year.

Under the deal, BCA will set up Beijing Shou Nong Future Bio-Tech Co. Ltd that will fund the development of the market and seek approval for commercial production of pigs resistant to the virus. This is expected to take several years and cost tens of millions of dollars, said Genus in a statement.

Genus shares surged more than 15% after the announcement and were on course for their best day in 17 years.

The deal with BCA is a first step towards getting the technology into China, which does not allow foreign firms to research and develop biotechnology in its market.

China has no regulatory framework on the use of gene-edited animals in the country which means BCA will need to lobby the government to create a regulatory framework to cover them.

BCA is owned by the Beijing Capital Agribusiness and Food Group, GLP-Youshan Fund and CITIC Agriculture, part of state-owned conglomerate CITIC.

Genus is also currently seeking approval from the U.S. Food and Drug Administration to commercialise the virus-resistant pigs in the United States.

Gene editing is a type of genetic engineering in which DNA is deleted, modified or replaced in the genome of a living organism.

It differs from genetic modification technology because it does not require introduction of genes from other species, a method that has caused controversy among consumers and regulators.

Beijing has not approved any commercial production of GMO food crops because of consumer fears around the technology.

Genus, worth 1.65 billion pounds ($2.12 billion) by market value, already produces and sells breeding stock in China to some of the country's top hog farmers.

Under the deal, Genus will receive upfront and milestone cash payments of $20 million subject to certain conditions being fulfilled.

After getting regulatory approval for the PRRS-resistant pigs in China, it will receive between $120 million and $160 million for the creation with BCA of a joint venture to include Genus's existing pig genetics operations in China.

Genus will also get royalties from the joint venture on sales in China of PRRS-resistant pigs.

PRRS often kills piglets and in some cases, also sows. It costs the U.S. and European hog industry about $2.5 billion each year in lost revenue, according to one estimate by the University of Edinburgh.

The companies also plan to work together on research into pigs resistant to African swine fever, an incurable virus that has spread rapidly in China since last year, and is set to reduce the herd by an estimated 200 million pigs.

(Reporting by Dominique Patton; editing by Kenneth Maxwell/Christian Schmollinger/Jane Merriman)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GENUS PLC
05/16GENUS : Strategic porcine collaboration in China
PU
05/16LONDON STOCK EXCHANGE : Financials, miners lead FTSE 100 rebound, but Burberry, ..
RE
05/16GENUS : shares surge on deal to market gene-edited pigs in China
RE
05/16GENUS : shares surge on deal to market gene-edited pigs in China
RE
03/25Medical device maker ConvaTec names Genus top boss as CEO
RE
03/25GENUS : Chief Executive Transition
PU
03/24CONVATEC : to appoint Karim Bitar from Genus as CEO - Sky News
RE
03/07GENUS PLC : Ex-dividend day for interim dividend
FA
2018LONDON STOCK EXCHANGE : Oil helps FTSE 100 end turbulent week firmer, but Brexit..
RE
2018GENUS : Result of placing to raise approximately £68m
PU
More news
Financials (GBP)
Sales 2019 486 M
EBIT 2019 64,0 M
Net income 2019 29,0 M
Debt 2019 73,7 M
Yield 2019 1,04%
P/E ratio 2019 57,52
P/E ratio 2020 37,75
EV / Sales 2019 3,76x
EV / Sales 2020 3,56x
Capitalization 1 750 M
Chart GENUS PLC
Duration : Period :
Genus plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENUS PLC
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 26,9  GBP
Spread / Average Target 0,15%
EPS Revisions
Managers
NameTitle
Karim Sani Nasib Bitar Chief Executive Officer & Executive Director
Robert Arthur Lawson Independent Non-Executive Chairman
Bill Christianson Chief Operating Officer
Stephen Wilson Group Finance Director & Executive Director
Jonathan Lightner Chief Scientific, Research & Development Officer
Sector and Competitors
1st jan.Capitalization (M$)
GENUS PLC25.35%2 212
IQVIA HOLDINGS INC16.05%26 592
LONZA GROUP25.17%23 527
CELLTRION, INC.--.--%19 888
INCYTE CORPORATION24.26%16 945
EXACT SCIENCES CORPORATION50.41%12 257